Literature DB >> 17882719

Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma.

M Putkonen1, A Rauhala, T-T Pelliniemi, K Remes.   

Abstract

BACKGROUND: Successful stem cell mobilization is a prerequisite for autologous blood cell transplantation. We analyzed factors that may predict the success of stem cell mobilization in patients with multiple myeloma (MM).
METHODS: We analyzed 124 consecutive patients and compared those who failed to mobilize a sufficient amount of CD34(+) cells (peak blood CD34(+) cell count <20x10(6)/L) (n=20) with those with successful mobilization (n=104). The peak blood CD34(+) cell count after mobilization was used as the marker of mobilization success against which the various predictive factors were tested.
RESULTS: In univariate analysis the best predictive factors for mobilization failure were the number of different chemotherapy regimens (P<0.001), number of chemotherapy cycles (P<0.001), time from diagnosis to mobilization (P<0.001) and previous use of IFN (P<0.001). The distributions of treatment responses at mobilization were similar in the groups with successful and unsuccessful mobilization, and were CR or VGPR in 10% of all patients, PR in 54% and stable or progressive disease in 36%. Regarding the mobilization-related factors, lower leukocyte nadir (P<0.001), longer duration of leukocyte counts <1x10(9)/L (P<0.001), lower platelet nadir (P=0.001), longer duration of platelet counts <20x10(9)/L (P<0.001) and the occurrence of sepsis after the mobilization therapy (P=0.001) were significantly associated with mobilization failure. In multivariate analysis, the amount of earlier chemotherapy cycles (P=0.002), low platelet nadir (P=0.020), occurrence of sepsis at mobilization (P=0.040) and previous use of IFN (P=0.052) remained as significant predictive factors for mobilization failure. DISCUSSION: Predicting the success of stem cell mobilization beforehand may have important practical consequences. By identifying those patients who will fail to mobilize stem cells, unnecessary mobilization and collection attempts can be avoided.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882719     DOI: 10.1080/14653240701508429

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  4 in total

1.  Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.

Authors:  Giuseppe Milone; Giovanni Tripepi; Massimo Martino; Flavia Ancora; Benedetta Bartolozzi; Andrea Spadaro; Chiara Nozzoli; Alessia La Fauci; Irene Amico; Salvatore Leotta; Massimo Poidomani; Giuseppe Irrera; Pasquale Iacopino; Riccardo Saccardi; Stefano Guidi; Alberto Bosi
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

Review 2.  Advances in stem cell mobilization.

Authors:  Rusudan K Hopman; John F DiPersio
Journal:  Blood Rev       Date:  2014-01-14       Impact factor: 8.250

3.  Poor hematopoietic stem cell mobilizers in multiple myeloma: a single institution experience.

Authors:  Guillermo J Ruiz-Delgado; Avril López-Otero; Ana Hernandez-Arizpe; Aura Ramirez-Medina; Guillermo J Ruiz-Argüelles
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-06-21       Impact factor: 2.576

Review 4.  Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

Authors:  Louis M Pelus; Sherif S Farag
Journal:  Stem Cells Cloning       Date:  2011-02-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.